Convenience Claims Can Put Companies On Slippery Promotional Ground
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cites an ad for Sanofi-Aventis' prostate cancer therapy Eligard for implying better patient quality of life and more physician efficiency because of less-frequent injections.
You may also be interested in...
Convenience Claims, Squinty Risk Info For Arbor's Nitro Spray Draw FDA Letter
Professional sales aid and DTC brochure for Nitrolingual Pumpspray claim the product is superior to tablets without substantial evidence, DDMAC says.
Convenience Claims, Squinty Risk Info For Arbor's Nitro Spray Draw FDA Letter
Professional sales aid and DTC brochure for Nitrolingual Pumpspray claim the product is superior to tablets without substantial evidence, DDMAC says.
Superiority Claims Based On Drug Delivery System Fail DDMAC Test
Shire overreached in claiming that the formulations for its ulcerative colitis drugs Lialda and Pentasa gave them an advantage, FDA says.